AOTMiT: Transparency Council, among others, vaccinations and off-label indications

The agenda includes:

1. Preparation of a position paper on the qualification of the health care benefit "Urine steroid profile"
2. Preparation of a position paper on the qualification of the health care benefit "Macroprolactin"
3. Preparation of a position paper on the qualification of the health care benefit "Inhibin B"
4. Preparation of a position paper on the evaluation of Prevenar 20, pneumococcal polysaccharide conjugated (20-valent, adsorbed) vaccine for the indication: prevention of pneumococcal infections in adults over 65 years of age.
5. Preparation of an opinion on the draft health policy program of the local government unit "Health policy program for prevention of RSV infections among children under 2 years of age in the Małopolska province, implementation years 2026-2030"
6. Preparation of an opinion on the draft health policy program of the local government unit "Program for the prevention of herpes zoster and postherpetic neuralgia among the residents of Lublin aged 55 - 64"
7. Preparation of an opinion on the active substance mycophenolas mofetil in off-label indications: treatment of pneumonia associated with hypersensitivity to organic dust, pulmonary sarcoidosis and inflammatory rheumatic diseases; other interstitial lung diseases (J84.8, J84.9).
8. Preparation of an opinion on the active substance mycophenolas mofetil in the off-label indication: interstitial lung disease and renal involvement in the course of autoimmune/autoinflammatory rheumatic disease.
9. Preparation of an opinion on the active substance carboplatin in combination with gemcitabine and nivolumab for an off-label indication: for the first-line treatment of urothelial carcinoma at a local stage beyond the possibilities of local treatment of a radical nature or at a generalized stage.
10. Preparation of an opinion on the active substance fentanylum (intranasal form) for the off-label indication: breakthrough pain in children with cancer who are receiving opioid maintenance therapy as part of the treatment of chronic cancer pain, and in whom there are documented contraindications to the use of other short-acting opioids or the ineffectiveness of these drugs has been established.
11. Preparation of an opinion on the active substance desmopressinum for the off-label indication: primary isolated bedwetting in patients between 5-6 years of age with normal urinary thickening ability after documenting the failure of 1-month supportive and motivational management.
12. Preparation of an opinion on the active substance carboplatinum for the following off-label indication: appendix C.6. C15 - malignant neoplasm of the esophagus
13. Preparation of an opinion on the active substance paclitaxelum for an off-label indication: appendix C.47.

• C15 - malignant neoplasm of the esophagus
• C21 - malignant neoplasm of the anus and anal canal.

Source: AOTMiT